In conclusion, it is worthwhile pondering over questions such as: what approaches are available to society to help patients who suffer from such rare disease? Can we continue to ignore such diseases and abandon those suffering from them to their fate? Therefore, the fate of orphan drugs is directly connected to the Orphan Drug Act. This "Act" was the first significant step that encouraged pharmaceutical companies to look at developing drugs for a smaller market. In deed, the "ADA", was responsible for the rapid introduction of several drugs to combat (HIV). Thus, the benefits manufactures received through "ADA" constitute a 50% federal tax credit for clinical research cost, exemption from FDA registration fees, exclusive market for seven years, protocol assistance and congressional grants of over 40 million. As you review these "numbers" it become very clear that obviously businesses have to be mandated to do the right thing.…
